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Abstract
Toll-like receptors (TLRs) play a crucial role in innate- and adaptive immunity. The TLR
pathways were shown to play key functional roles in experimental acute and chronic kidney
injury, including the allo-immune response after experimental renal transplantation. Data
about the precise impact of TLRs and their negative regulators on human renal transplant
outcomes however are limited and contradictory. We studied twelve non-synonymous sin-
gle nucleotide polymorphisms (SNPs) of which eleven in TLR1-8 and one in SIGIRR in a
final cohort comprising 1116 matching donors and recipients. TLR3 p.Leu412Phe and
SIGIRR p.Gln312Arg significantly deviated from Hardy-Weinberg equilibrium and were
excluded. The frequency distribution of the minor alleles of the remaining 10 TLR variants
were compared between patients with end-stage renal disease (recipients) and controls
(kidney donors) in a case-control study. Secondly, the associations between the minor
allele frequency of the TLR variants and delayed graft function, biopsy-proven acute rejec-
tion and death-censored graft failure after transplantation were investigated with Cox
regression. Carrier frequencies of the minor alleles of TLR1 p.His305Leu (OR = 4.79, 95%
CI = 2.35–9.75, P = 0.0002), TLR1 p.Asn248Ser (OR = 1.26, 95% CI = 1.07–1.47, P = 0.04)
and TLR8 p.Met1Val (OR = 1.37, 95% CI = 1.14–1.64, P = 0.008) were significantly higher
in patients with ESRD, with little specificity for the underlying renal disease entity (adjusted
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for age, gender and donor-recipient relatedness). The minor allele frequency of none of the
TLR variants significantly associated with the surrogate and definite outcomes, even when
multivariable models were created that could account for TLR gene redundancy. In conclu-
sion, genetic variants in TLR genes were associated with the prevalence of ESRD but not
renal transplant outcomes. Therefore, our data suggests that specific TLR signaling routes
might play a role in the final common pathway of primary renal injury. A role for TLR signal-
ing in the context of renal transplantation is probably limited.
Introduction
Toll-like receptors (TLRs) are pattern recognition receptors (PRR), which can be activated by
both pathogen-associated molecular patterns (PAMPs) and endogenous ligands called dam-
age-associated molecular patterns (DAMPs) leading to the induction of an inflammatory
response [1, 2]. Single Ig IL-1-related receptor (SIGIRR) is one of the negative regulators of the
TLR signalling pathway and is involved in reducing inflammation upon TLR activation to pre-
vent excessive inflammation [3, 4]. TLRs play a part in both the innate and the subsequent
adaptive immunity and are of special interest in renal diseases; TLRs are expressed on murine
and human leukocytes and renal endothelial and epithelial cells, including podocytes [1, 2].
TLRs are crucial in the antibacterial defence mechanisms during renal infection, however this
immune response is detrimental during a sterile inflammatory response including acute and
chronic kidney injury and the allo-immune response after transplantation [2, 5]. In renal trans-
plant patients, TLR4 is the most frequently studied TLR family member that is activated by
DAMPs that are released during an episode of renal injury and in particular during ischemia-
reperfusion injury after long-term cold storage of the transplants. One of the most well-known
DAMPs recognized by TLR4 is High-mobility group protein B1 (HMGB1), which is highly
expressed in renal transplants of deceased but not living donors after surgery [6]. Different
studies have shown that if the donor or recipient inherits or possess a TLR4 loss-of-function
single nucleotide polymorphisms (SNPs) such as p.Asp299Gly allele A/G and p.Thr399Ile
allele C/T, recipients were less likely to experience delayed graft function (DGF) or acute rejec-
tion (AR) [7, 8]. Importantly, recipients with these particular TLR4 variants experienced more
episodes of infections [7] highlighting a possible double-edge sword for TLRs in the context of
transplantation. Unfortunately, there are conflicting data on the role of TLR4 and other TLR
signalling sequence variants on renal outcome in renal transplant recipients [7–18]. This might
be explained by the variety in the patient databases that have been used. In addition, studies
vary in their definition of study endpoints or studies use only one single endpoint [7–18].
Large cohorts that are adequately powered to investigate the impact of especially multiple
SNPs are needed since these pattern recognition receptors are known to be redundant. The aim
of the current study is therefore to investigate the impact of SNPs in genes that are involved in
TLR pathways on outcomes in the context of renal transplantation.
Material and Methods
Study population
Samples were included from a study cohort as described before [19,20]. Between March 1993
and February 2008, 1271 matching donor and recipient peripheral blood mononuclear cells
(PBMCs) were obtained from patients who underwent kidney transplantation at the University
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Medical Center Groningen, The Netherlands. The exclusion criteria were: cases of re-trans-
plantation, combined kidney/pancreas or kidney/liver transplantation, technical problems dur-
ing surgery, the unavailability of DNA and loss to follow-up. The institutional ethical review
board of the University Medical Center Groningen approved the study (METc 2014/077).
Written informed consent was obtained from all patients. None of the living transplant donors
were from a vulnerable population and all living donors provided written informed consent. In
case of deceased donation, the donors provided informed consent when they registered their
donation status and by law, no additional consent was needed. The study was conducted
according to the principles of the declaration of Helsinki. The final statistical analyses were per-
formed on 1116 individuals (2232 samples), corresponding to 92% of the donor and recipient
pairs after exclusion of patients with primary non-functioning grafts (see below).
DNA isolation, quality control and SNP selection criteria
DNA samples were analyzed for absorbance at 260 nm with NanoDrop spectrophotometer
(ND–1000, NanoDrop Technologies) and DNA concentration was calculated by the Nano-
Drop nucleic acid application module. As a measure of DNA purity 260/280 and 260/230
absorbance ratios were assessed. Where samples failed to meet the minimum DNA concentra-
tion and purity recommended for Illumina genotyping, repeated isolation attempts were made.
In this study, 12 non-synonymous SNPs in TLR and SIGIRR genes obtained from NCBI (inclu-
sion criterion: minor allele frequency>1%) were analyzed for their association with the various
renal outcomes as defined below. Genotyping of the selected SNP was performed using the Illu-
mina VeraCode GoldenGate Assay kit (Illumina, San Diego, CA, USA) according to the manu-
facturer’s instructions. Genotype clustering and calling was performed using Beadstudio
Software (Illumina). Of the chosen SNPs, rs4986790 (TLR4 p.Asp299Gly) and rs4986791
(TLR4 p.Thr399Ile) are in linkage disequilibrium (LD) (r2 = 1, SNP Annotation and Proxy
Search, Broad institute).
Case-control study for end-stage renal disease
We performed a case-control study to investigate the association between the TLR SNPs and
the prevalence of end-stage renal disease by comparing the recipients as cases with the donors
as their respective controls. Cases were separately evaluated for the association of the allele fre-
quencies of the variants in specific groups of renal diseases, namely congenital nephropathy
(N = 216), immunecomplex-mediated glomerulonephritis (N = 299), infective pyelonephritis
(N = 126) and renovascular disease (N = 102) with the full group of controls (donors,
N = 1116). We took into account that donors and recipients are related in case of living related
renal transplantation.
Study endpoints for longitudinal analyses after transplantation
The endpoints used in longitudinal analyses were: delayed graft function (DGF), defined as the
requirement for dialysis within the first week after transplantation due to the need for addi-
tional renal replacement therapy (patients with subsequent non-functioning and loss of their
allograft, referred to as primary non-function (PNF, N = 60) [19], were excluded from analy-
ses), time to the first episode of biopsy-proven acute rejection (BPAR) and death-censored
graft failure (defined as the need for dialysis or re-transplantation, patients with PNF were
excluded). Data on rejection type (antibody- or T cell-mediated rejection) was unavailable due
to the lack of a standardized method for the determination of donor-specific antibodies over
time.
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Statistical analyses
Statistical analyses were performed using the R platform for statistical computing version 3.1.1.
(www.r-project.org) and PLINK version 1.07 for Mac OS X 10.10.4 (S. Purcell, http://pngu.
mgh.harvard.edu/purcell/plink) [21]. We followed the protocol for statistical analyses in
genetic studies as described by Clarke et al. [22]. Two-sided P-values<0.05 were considered
statistically significant after Bonferroni correction for multiple comparisons. Minor allele fre-
quencies were calculated as the sum of the minor alleles divided by 2 times the total number of
patients. Hardy-Weinberg equilibria for the variants in the donors (as a healthy control group)
were calculated and when SNPs were in disequilibrium (after Bonferroni correction), they were
excluded from further analyses. In the case-control study, odds ratios and corresponding 95%
confidence intervals were calculated with additive genetic logistic regression models correcting
for age and gender. Donor-recipient relatedness in case of living related renal transplantation
was taken into consideration by applying the DFAM algorithm in PLINK. Because we had a
large database with a fixed amount of patients before genotyping started, type II error percent-
ages (100%—power) for the significantly associated variants were calculated post-hoc according
to the statistical methods as described by Skol et al. [23]. The prevalence of end-stage renal dis-
ease in The Netherlands was estimated at 0.1% based on the number of patient on renal
replacement therapy at time of analysis. The association between single TLR variants and
delayed graft function was calculated with univariable logistic regression models and the odds
ratios with corresponding 95% confidence intervals were presented. The association between
single TLR variants and biopsy-proven acute rejection and death-censored graft failure was cal-
culated with univariable Cox regression models and the hazard ratios with corresponding 95%
confidence intervals were presented. Corresponding P-values were calculated with log rank
tests. In the regression models, all P-values underwent Bonferroni correction for multiple com-
parisons. For the 3 endpoints, we next constructed multivariable models per endpoint that
included parameters that are known to influence these endpoints (e.g. cold ischemia time for
delayed graft function) and compared these clinical models to models that additionally
included all TLR variants in both donors and recipients in order to account for gene redun-
dancy. We used the Akaike information criterion (AIC) to compare the relative goodness-of-fit
of the models for their association with the endpoints. Lower AIC values are indicative of a bet-
ter goodness-of-fit of the model. In this way we wanted to investigate whether including all
TLR variants in one multivariable model as a method to account for redundancy between
TLRs genes, might provide additional information besides parameters that have been known to
influence the outcomes. In this case, the role of all TLR variants as a group rather than the pos-
sible role for a single variant is investigated.
Results
Study characteristics and distribution of the TLR gene variants
Fig 1 shows the flowchart of the in- and excluded patients and samples. The characteristics of
cohort are presented in Table 1. There were no significant differences in donor, recipient and
transplant characteristics between the included and excluded patient cohorts, which supports
our statement that inclusion was not systematically biased. The genotypic distributions of the
SNPs in donors and recipients are displayed in Table 2. Of the total of 1211 patients included
in the study, 1116 (92%) had all donor and recipient SNPs determined. After Bonferroni cor-
rection for multiple testing, TLR3 p.Leu412Phe (P = 0.046) and SIGIRR p.Gln312Arg
(P< 0.0001) appeared in Hardy-Weinberg disequilibrium in controls (donors) and these SNPs
were therefore excluded from further analysis.
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Frequency distribution of the variant alleles comparing patients with end-
stage renal disease and healthy controls
We wanted to find out whether there was a difference in the carrier distribution of the minor
allele alleles between patients with end-stage renal disease (recipients) and healthy controls
(donors) in a case-control approach. After correction for multiple comparisons, age, gender
and donor-recipient relatedness, the carrier frequency of the minor allele for TLR1 p.
His305Leu (OR = 4.79, 95% CI = 2.35–9.75, P = 0.0002), TLR1 p.Asn248Ser (OR = 1.26, 95%
CI = 1.07–1.47, P = 0.04) and TLR8 p.Met1Val (OR = 1.37, 95% CI = 1.14–1.64, P = 0.008) was
significantly higher in patients with end-stage renal disease (Table 3). In Table 4, we separated
the patients by cause of end-stage renal disease in order to investigate whether the carrier fre-
quency of the minor alleles for the TLR variants showed specificity for certain underlying dis-
ease entities. The minor allele for TLR1 p.His305Leu showed the strongest association with
each of the underlying renal disease group tested: congenital nephropathy (OR = 4.94, 95%
Fig 1. Flowchart of the in- and excluded samples.
doi:10.1371/journal.pone.0139769.g001
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CI = 2.26–10.84, P = 0.0002), immunecomplex-mediated glomerulonephritis (OR = 4.91, 95%
CI = 2.31–10.41, P = 0.0001), infective pyelonephritis (OR = 6.71, 95% CI = 3.10–14.53,
P< 0.0001) and renovascular disease (OR = 4.37, 95% CI = 1.83–10.43, P = 0.003). TLR1 p.
Asn248Ser and TLR8 p.Met1Val showed some specificity for immunecomplex-mediated
glomerulonephritis (respectively OR = 1.33, 95% CI = 1.05–1.67, P = 0.05 and OR = 1.52, 95%
CI = 1.18–1.97, P = 0.004) and renovascular disease (respectively OR = 1.53, 95% CI = 1.10–
2.11, P = 0.03 and OR = 1.86, 95% CI = 1.25–2.77, P = 0.002), however the estimated type II
error ranged between 9–28%.
Role of TLR sequence variants in relation to delayed graft function
Delayed graft function (DGF) occurred in 328 of 1116 patients (29%). DGF was observed in
37% (317/867) of recipients receiving a graft from a deceased donor and 4% (11/249) in recipi-
ents of a living donor. We analysed the association of TLR SNPs with DGF in all included
patients and separately in recipients of a deceased donor, since TLR activation is more promi-
nently observed in the context of deceased donation [6]. In univariable analyses, where all
Table 1. Characteristics of the study group, subdivided by included and excluded patients.
Variable TotalN = 1271 IncludedN = 1116 ExcludedN = 155 P-value1
Donor characteristics
Age (mean years ± SD) 44 ± 14 45 ± 14 44 ± 16 1
Male N (%) 645 (51%) 554 (50%) 91 (59%) 0.7
Donor type N (%)
Living donor 282 (22%) 249 (22%) 33 (21%) 1
Deceased donor (DBD + DCD) 989 (78%) 867 (78%) 122 (79%)
Recipient characteristics
Age (mean years ± SD) 48 ± 13 48 ± 13 48 ± 13 1
Male N (%) 739 (58%) 655 (59%) 84 (54%) 1
Initial immunosuppression N (%)
Corticosteroids 1201 (95%) 1053 (94%) 148 (95%) 1
Calcineurin inhibitor (CsA or TAC) 1182 (93%) 1039 (93%) 143 (92%) 1
Proliferation inhibitor (MPA or AZA) 979 (77%) 863 (77%) 116 (75%) 1
mTOR inhibitor 38 (3%) 31 (3%) 7 (5%) 1
Induction therapy N (%)
Anti-thymocyte globulin 103 (8%) 90 (8%) 13 (8%) 1
Anti-CD3 moab 19 (2%) 15 (1%) 4 (3%) 1
Interleukin–2 receptor antagonist 199 (16%) 171 (15%) 28 (18%) 1
First transplant N (%) 1143 (90%) 1001 (90%) 142 (92%) 1
Transplant characteristics
Cold ischemia time (mean hours ± SD)
Living donors 2.7 ± 1.9 2.7 ± 2.0 2.6 ± 0.7 1
Deceased donors 20.7 ± 6.5 20.6 ± 6.4 21.6 ± 6.8 1
HLA no. of 0 mismatches N (%)2 241 (23%) 213 (23%) 28 (22%) 1
DBD = deceased brain death, DCD = deceased cardiac death, SD = standard deviation, CsA = cyclosporine A, TAC = tacrolimus, MPA = mycophenolic
acid, AZA = azathioprine, mTOR = mammalian target of rapamycin, moab = monoclonal antibody, HLA = human leukocyte antigen. HLA = Human
leukocyte antigen.
1Bonferroni corrected for multiple testing
2Data for N = 221 were missing; N = 195 (20%) in the included patients, N = 26 in the excluded (17%), P = 0.9.
doi:10.1371/journal.pone.0139769.t001
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Table 2. Allele frequency distributions and possible phenotypical consequences of the single nucleotide polymorphisms in TLR-related genes.






























































































60.8 34.2 5.0 22.1 51.2 47.0 1.8 25.4 38.3 49.2 12.5 37.1
Donor and recipient genotype are displayed as dominant (A/A), heterozygous (A/a) or recessive (a/a). Chr = chromosome, HGVS = Human Genome
Variation Society LOF = loss of function, GOF = gain of function, ND = not determined, MAF = minor allele frequency.
doi:10.1371/journal.pone.0139769.t002
Table 3. Case-control study for the association between TLR single nucleotide polymorphsims and end-stage renal disease.
Gene HGVS name MAF cases (%) MAF controls (%) OR1 95% CI1 P-value2 Type II error when P < 0.053
TLR1 p.His305Leu 9.5 2.6 4.79 2.35–9.75 0.0002 0%
TLR1 p.Asn248Ser 30.0 25.9 1.26 1.07–1.47 0.04 6%
TLR2 p.Arg753Gln 9.6 5.1 0.73 0.22–2.43 1
TLR4 p.Asp299Gly 5.8 5.4 1.27 0.52–3.12 1
TLR4 p.Thr399Ile 6.0 5.5 1.77 0.57–5.51 1
TLR5 p.Arg392Ter 8.2 7.1 2.93 1.03–8.33 0.4
TLR5 p.Phe616Leu 44.6 42.6 0.92 0.82–1.04 1
TLR6 p.Ser249Pro 38.6 41.0 0.92 0.81–1.04 1
TLR7 p.Gln11Leu 21.7 21.1 1.05 0.85–1.30 1
TLR8 p.Met1Val 27.9 22.6 1.37 1.14–1.64 0.008 1%
1Per allele odds ratios (OR) and 95% conﬁdence intervals (CI) based on additive genetic logistic regression models adjusted for age and gender, taking
case-control relatedness into consideration (DFAM algorithm). HGVS = Human Genome Variation Society.
2P-values are Bonferroni corrected.
3Estimates of the type II errors (100%–power) were calculated according to the methods by Skol et al. [23] with the data as mentioned in the table and an
end-stage renal disease prevalence of 0.1% (estimate in The Netherlands).
doi:10.1371/journal.pone.0139769.t003
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donor and recipient SNPs were tested separately, none of the TLR SNPs associated with DGF
after Bonferroni correction (Table 5). As expected, cold ischemia time (P< 0.0001), donor age
(P = 0.0008) and recipient age (P = 0.0005) were significantly associated with the occurrence of
DGF. The model that included these 3 parameters had an Akaike information criterion (AIC)
of 1272.5. Since TLRs are highly redundant, we also tested the performance of a logistic regres-
sion model that included all TLR variants in one multivariable model. Adding all donor and
recipient SNPs to the crude multivariable model of cold ischemia time, donor age and recipient
age again resulted in a higher AIC (1289.4), showing no additional value for variants in TLR
genes in explaining the occurrence of DGF. Similar results were obtained when only recipients
of a deceased donor were analysed (S1 Table). We therefore conclude that variants in TLR
genes are not associated with the occurrence of delayed graft function after transplantation.
Role of TLR sequence variants in relation to acute rejection
The median time of freedom-of-rejection was 51 months (interquartile range 1–105 months).
The overall cumulative incidence of biopsy-proven acute rejection (BPAR) after renal trans-
plantation was 34% (378/1116). In univariable analyses, where all donor and recipient SNPs
were tested separately, none of the SNPs in the TLR genes associated with BPAR after Bonfer-
roni correction (Table 6). In our cohort, most of the variation in the occurrence of BPAR could
be explained by a preceding period of DGF (P = 0.01), recipient age (P< 0.0001) and the num-
ber of HLA mismatches (P< 0.0001), which resulted in an AIC of 4125.6. When we added all
donor and recipient TLR variants to the model that included DGF, recipient age and number










OR1 95% CI1 P-
value2
Type II error when
P < 0.053
TLR1 p.His305Leu Congenital 216 10.4 2.6 4.94 2.26–
10.84
0.0002 0%
Glomerulonephritis 299 8.4 2.6 4.91 2.31–
10.41
0.0001 0%
Pyelonephritis 126 11.5 2.6 6.71 3.10–
14.53
<0.0001 0%





Congenital 216 25.9 25.9 1.02 0.76–1.37 1
Glomerulonephritis 299 32.6 25.9 1.33 1.05–1.67 0.05 16%
Pyelonephritis 126 27.0 25.9 1.27 0.94–1.71 0.4
Renovascular 102 33.3 25.9 1.53 1.10–2.11 0.03 28%
TLR8 p.Met1Val Congenital 216 24.6 22.6 1.18 0.86–1.64 0.9
Glomerulonephritis 299 29.4 22.6 1.52 1.18–1.97 0.004 9%
Pyelonephritis 126 28.1 22.6 1.24 0.85–1.81 0.8
Renovascular 102 33.6 22.6 1.86 1.25–2.77 0.002 17%
1Per allele odds ratios (OR) and 95% conﬁdence intervals (CI) based on additive genetic logistic regression models adjusted for age and gender, taking
case-control relatedness into consideration (DFAM algorithm). HGVS = Human Genome Variation Society.
2P-values are Bonferroni corrected.
3Post hoc estimates of the type II errors (100%–power) were calculated according to the methods by Skol et al. [23] with the data as mentioned in the
table and an end-stage renal disease prevalence of 0.1% (estimate in The Netherlands).
doi:10.1371/journal.pone.0139769.t004
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of HLA mismatches, again a higher AIC was calculated (AIC = 4142.0), indicating no addi-
tional explanatory value by the TLR variants for the cumulative incidence of BPAR.
Role of TLR sequence variants in relation to graft failure
Median overall graft survival was 5.5 years (interquartile range 2.9–8.9 years). The overall
cumulative incidence of death-censored graft failure was 191/1116 (17%) of which 124/215
(66%, 11% of total) failed due to rejection. In line with our negative findings concerning the
lack of association of the TLR variants with the surrogate endpoints DGF and BPAR, none of
the variants associated with the cumulative incidence of death-censored graft failure (Table 7).
In our cohort, patients that underwent an episode of BPAR had worse death-censored graft
survival (P< 0.0001, AIC = 2504.3). Again, a multivariable model that included all donor and
recipient TLR variants plus the occurrence of an episode of BPAR did not improve the good-
ness-of-fit of the model (AIC = 2530.2), therefore indicating no additional value for the TLR
variants in explaining the development of death-censored graft failure after transplantation.
Discussion
TLR-signaling and control by their negative regulators is of special interest in renal diseases
because of their expression pattern in murine and human kidneys and the role they play in
Table 5. Association of TLR single nucleotide polymorphism with delayed graft function in univariable logistic regression analysis.
Gene HGVS name Allele combination1 Donor Recipient
OR 95% CI P-value2 OR 95% CI P-value2
TLR1 p.His305Leu T/a 0.69 0.34–1.30 1 1.12 0.75–1.67 1
a/a 2.37 0.09–60.01 1 0.55 0.23–1.13 1
TLR1 p.Asn248Ser C/t 0.86 0.65–1.13 1 0.85 0.64–1.12 1
t/t 0.65 0.37–1.11 1 1.64 1.07–2.50 0.4
TLR2 p.Arg753Gln G/a 0.71 0.44–1.11 1 0.74 0.52–1.04 1
a/a - - - - - -
TLR4 p.Asp299Gly A/g 1.30 0.86–1.94 1 0.82 0.53–1.24 1
g/g 2.48 0.10–62.79 1 1.18 0.05–12.33 1
TLR4 p.Thr399Ile C/t 1.28 0.85–1.90 1 0.85 0.56–1.28 1
t/t - - - 1.18 0.05–12.37 1
TLR5 p.Arg392Ter G/a 1.35 0.94–1.93 1 1.08 0.75–1.54 1
a/a - - - 1.46 0.30–6.00 1
TLR5 p.Phe616Leu A/g 0.92 0.69–1.24 1 0.78 0.59–1.05 1
g/g 1.15 0.80–1.67 1 0.88 0.60–1.28 1
TLR6 p.Ser249Pro G/a 1.00 0.75–1.33 1 0.91 0.68–1.20 1
a/a 0.97 0.66–1.41 1 1.01 0.69–1.46 1
TLR7 p.Gln11Leu A/t 0.88 0.63–1.23 1 0.83 0.57–1.19 1
t/t 1.25 0.83–1.85 1 0.74 0.48–1.09 1
TLR8 p.Met1Val A/g 0.96 0.68–1.34 1 1.09 0.77–1.55 1
g/g 1.04 0.70–1.53 1 1.12 0.80–1.54 1
OR = odds ratio (1per allele combination as compared to the homozygous dominant allele combination)
CI = conﬁdence interval, HGVS = Human Genome Variation Society. The results represent univariable crude models, i.e. no other independent variables
were included.
2P-values are Bonferroni corrected.
doi:10.1371/journal.pone.0139769.t005
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experimental models of acute and chronic renal injury [46–55]. Contribution of other TLRs
(besides the TLR2-4-6 axis) on progression to pre-transplant ESRD and renal outcome after
transplantation is a relatively unexplored field. In this large cohort of renal transplant recipi-
ents, we observed that 1) TLR1 p.His305Leu, TLR1 p.Asn248Ser and TLR8 p.Met1Val signifi-
cantly associated with the prevalence of end-stage renal disease, and 2) SNPs in TLR genes do
not explain the occurrence of delayed graft function, biopsy-proven acute rejection and subse-
quently death-censored graft failure after transplantation.
Thus far, relatively few studies have investigated the contribution of non-synonymous poly-
morphisms in TLR-related genes and their association with renal diseases of the native kidneys
and the development of chronic kidney disease (CKD) [12,56–62]. Table 8 summarizes the
studies that we could identify from the literature in which the same TLR variants were analyzed
as in our study. Lee et al. described a higher frequency of the minor allele for TLR1 p.Asn248-
Ser in pediatric patients with IgA nephropathy as compared to healthy controls [56], which
might be compared to the higher frequency of the minor allele for this variant in patients with
immunecomplex-mediated glomerulonephritis in our cohort. Unfortunately, in this study
TLR1 p.His305Leu, the variant that showed a robust and very relevant association with end-
stage renal disease in our cohort, was not investigated. TLR4 p.Asp299Gly and p.Thr399Ile are
by far the most studied TLR variants in the literature [12,58–62]. Only the study by Akil et al.
found a significant association between the minor allele frequency of any of the two TLR4
Table 6. Association of TLR single nucleotide polymorphism with biopsy-proven acute rejection.
Gene HGVS name Allele combination1 Donor Recipient
HR 95% CI P-value2 HR 95% CI P-value2
TLR1 p.His305Leu T/a 0.68 0.39–1.18 1 1.60 1.20–2.12 0.1
a/a 1.86 0.26–13.21 1.02 0.60–1.74
TLR1 p.Asn248Ser C/t 0.97 0.78–1.20 1 1.09 0.88–1.35 1
t/t 1.37 0.95–1.98 1.04 0.72–1.48
TLR2 p.Arg753Gln G/a 0.84 0.59–1.20 1 1.32 1.04–1.68 0.9
a/a - - 2.92 0.41–20.84
TLR4 p.Asp299Gly A/g 0.85 0.60–1.20 1 0.90 0.65–1.25 1
g/g - - 1.05 0.15–7.49
TLR4 p.Thr399Ile C/t 0.91 0.65–1.27 1 0.94 0.68–1.30 1
t/t - - 1.06 0.15–7.53
TLR5 p.Arg392Ter G/a 1.00 0.75–1.34 0.3 0.80 0.59–1.09 1
a/a 10.52 1.47–75.19 1.04 0.33–3.24
TLR5 p.Phe616Leu A/g 1.08 0.85–1.36 1 0.92 0.74–1.16 1
g/g 1.03 0.76–1.38 0.97 0.72–1.30
TLR6 p.Ser249Pro G/a 0.89 0.72–1.12 1 0.73 0.59–0.92 0.1
a/a 0.86 0.64–1.16 1.06 0.81–1.40
TLR7 p.Gln11Leu A/t 0.99 0.76–1.28 1 0.91 0.68–1.22 1
t/t 1.25 0.92–1.28 1.17 0.88–1.56
TLR8 p.Met1Val A/g 1.25 0.98–1.61 1 1.07 0.81–1.41 1
g/g 0.96 0.70–1.32 1.20 0.93–1.54
HR = hazard ratio (1per allele combination as compared to the homozygous dominant allele combination)
CI = conﬁdence interval, HGVS = Human Genome Variation Society. The results represent univariable crude models, i.e. no other independent variables
were included.
2P-values are calculated by log rank tests after Bonferroni correction for multiple comparisons.
doi:10.1371/journal.pone.0139769.t006
Toll-Like Receptor Polymorphisms in Renal Transplantation
PLOS ONE | DOI:10.1371/journal.pone.0139769 October 7, 2015 10 / 17
variants and the prevalence of chronic kidney disease [60]. The vast majority of studies how-
ever did not find an association, which is in line with our study and because p.Asp299Gly and
p.Thr399Ile are in high linkage disequilibrium, one would expect a similar effect for both vari-
ants in this case. Interestingly, two [60,61] of three studies [60–62] found an association of the
minor allele frequency for the TLR4 variant p.Asp299Gly with pyelonephritis (both with and
without secondary chronic kidney disease), which could unfortunately not be investigated in
such detail in our study. In line with our study, Cheng et al. did not find an association of the
minor allele of TLR5 variant p.Arg392Ter with native kidney diseases [57]. The residual TLR
variants, which includes TLR8 p.Met1Val that showed an association with end-stage renal dis-
ease in our cohort, have not been described before. Due to the lack of functional TLR pathway
testing in patients carrying these TLR SNPs associated with end-stage renal disease, we con-
sider our study hypothesis-generating.
Chronic renal allograft failure on the other hand is known to develop from both immune
and non-immune damage to the graft. In our study we were unable to show an association of
any of the TLR SNPs in either donor or recipient with surrogate and definite outcomes. Table 8
provides a list of the same TLR SNPs and their association with transplant outcomes as
described in the literature [7,8,12,13,18,58,63]. Comparable to our study, Krüger et al. [13] and
Mutlubas et al. [58] did not identify an association of TLR2 p.Arg753Gln with renal transplant
outcomes. In the context of renal transplantation, TLR4 p.Asp299Gly and p.Thr399Ile are also
Table 7. Association of TLR single nucleotide polymorphism with death-censored graft survival.
Gene HGVS name Allele combination1 Donor Recipient
HR 95% CI P-value2 HR 95% CI P-value2
TLR1 p.His305Leu T/a 1.02 0.52–2.00 1 1.01 0.65–1.56 1
a/a - - 0.56 0.23–1.37
TLR1 p.Asn248Ser C/t 1.13 0.84–1.52 1 1.11 0.82–1.50 1
t/t 0.93 0.51–1.69 1.44 0.92–2.24
TLR2 p.Arg753Gln G/a 1.13 0.72–1.77 1 1.29 0.93–1.80 1
a/a - - - -
TLR4 p.Asp299Gly A/g 1.15 0.74–1.80 1 0.80 0.50–1.29 1
g/g - - - -
TLR4 p.Thr399Ile C/t 1.17 0.76–1.81 1 0.74 0.45–1.20 1
t/t - - - -
TLR5 p.Arg392Ter G/a 1.31 0.90–1.90 1 0.84 0.55–1.27 1
a/a - - 0.77 0.11–5.52
TLR5 p.Phe616Leu A/g 1.03 0.75–1.43 1 1.20 0.87–1.64 1
g/g 0.82 0.53–1.28 0.70 0.44–1.13
TLR6 p.Ser249Pro G/a 1.19 0.87–1.64 1 0.85 0.62–1.17 1
a/a 0.96 0.62–1.48 1.08 0.73–1.61
TLR7 p.Gln11Leu A/t 0.83 0.57–1.19 1 0.89 0.59–1.35 1
t/t 0.96 0.61–1.50 1.41 0.96–2.06
TLR8 p.Met1Val A/g 0.99 0.68–1.44 1 1.05 0.71–1.56 1
g/g 1.20 0.80–1.80 1.28 0.91–1.82
HR = hazard ratio (1per allele combination as compared to the homozygous dominant allele combination)
CI = conﬁdence interval, HGVS = Human Genome Variation Society. The results represent univariable crude models, i.e. no other independent variables
were included.
2P-values are calculated by log rank tests after Bonferroni correction for multiple comparisons.
doi:10.1371/journal.pone.0139769.t007
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Table 8. Association of the TLR gene polymorphisms with renal outcomes as described in the literature.
Gene HGVS name Author, year Reference Country Native / Transplant Disease Controls Effect of the minor allele
TLR1 p.His305Leu - - - - - - -
TLR1 p.Asn248Ser Lee, 2011 [56] Korean Native GN Healthy Increased risk
Cheng, 2013 [57] Taiwan Native PN no PN No effect
TLR2 p.Arg753Gln Mutlubas, 2009 [58] Turkey Native CKD Healthy Increased risk
Soylu, 2010 [59] Turkey Native GN no GN No effect
Krüger, 2010 [13] Germany Transplant DGF no DGF No effect
Krüger, 2010 [13] Germany Transplant AR no AR No effect
Mutlubas, 2009 [58] Turkey Transplant GF no GF No effect
Krüger, 2010 [13] Germany Transplant GF no GF No effect
TLR4 p.Asp299Gly Nogueira, 2007 [12] Brazil Native CKD Healthy No effect
Mutlubas, 2009 [58] Turkey Native CKD Healthy No effect
Akil, 2012 [60] Turkey Native CKD no CKD Increased risk
Bayram, 2013 [62] Turkey Native CKD no CKD No effect
Soylu, 2010 [59] Turkey Native GN no GN No effect
Karoly, 2007 [61] Hungary Native PN no PN Increased risk
Akil, 2012 [60] Turkey Native PN no PN Increased risk
Bayram, 2013 [62] Turkey Native PN no PN No effect
Nogueira, 2007 [12] Brazil Transplant DGF2 no DGF2 No effect
Krüger, 2010 [13] Germany Transplant DGF2 no DGF2 No effect
Ducloux, 2005 [7] France Transplant AR2 no AR2 Decreased risk
Palmer, 2006 [8] United States Transplant AR1 no AR1 Decreased risk
Fekete, 2006 [63] Hungary Transplant AR2 no AR2 Decreased risk
Nogueira, 2007 [12] Brazil Transplant AR2 no AR2 No effect
Krüger, 2010 [13] Germany Transplant AR2 no AR2 No effect
Krichen, 2013 [18] Tunesia Transplant AR2 no AR2 No effect
Nogueira, 2007 [12] Brazil Transplant PN2 no PN2 No effect
Ducloux, 2005 [7] France Transplant GF2 no GF2 No effect
Mutlubas, 2009 [58] Turkey Transplant GF2 no GF2 No effect
Krüger, 2010 [13] Germany Transplant GF2 no GF2 No effect
TLR4 p.Thr399Ile Nogueira, 2007 [12] Brazil Native CKD Healthy No effect
Mutlubas, 2009 [58] Turkey Native CKD Healthy No effect
Bayram, 2013 [62] Turkey Native CKD no CKD No effect
Soylu, 2010 [59] Turkey Native GN no GN No effect
Nogueira, 2007 [12] Brazil Transplant DGF no DGF2 No effect
Krüger, 2010 [13] Germany Transplant DGF no DGF2 No effect
Ducloux, 2005 [7] France Transplant AR2 no AR2 Decreased risk
Palmer, 2006 [8] United States Transplant AR1 no AR1 Decreased risk
Nogueira, 2007 [12] Brazil Transplant AR2 no AR2 No effect
Krüger, 2010 [13] Germany Transplant AR2 no AR2 No effect
Nogueira, 2007 [12] Brazil Transplant PN2 no PN2 No effect
Ducloux, 2005 [7] France Transplant GF2 no GF2 No effect
Mutlubas, 2009 [58] Turkey Transplant GF2 no GF2 No effect
Krüger, 2010 [13] Germany Transplant GF2 no GF2 No effect
TLR5 p.Arg392Ter Cheng, 2013 [57] Taiwan Native PN no PN No effect
Krüger, 2010 [13] Germany Transplant DGF no DGF No effect
Krüger, 2010 [13] Germany Transplant AR no AR No effect
Krüger, 2010 [13] Germany Transplant GF no GF No effect
(Continued)
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among the most studied TLR SNPs [7,8,12,13,18,58,63]. Contrary to the well-known role for
TLR4 in experimental ischemia-reperfusion injury, none of the studies (including the current)
found an association with either of the two TLR4 SNPs with the development of delayed graft
function [12,13]. Delayed graft function is a heterogeneous and arbitrary outcome measure,
that includes the effect of donation type, donor/recipient age, ischemia times (cold and warm)
but also allo-immune phenomena, which makes a direct comparison with experimentally con-
trolled ischemia-reperfusion injury difficult and this difference should be taken into account
when interpreting genetic analyses. A potential role for TLR4 SNPs in the context of acute
rejection generated conflicting results with half of the studies describing a protective effect
[7,8,63] and half of the studies describing no effect at all [12,13,18]. Our study, which is the
largest investigating both TLR4 SNPs to date, is in line with the latter studies. Interestingly,
none of the studies (including the current) describes an effect on the cumulative incidence of
graft failure [7,13,58]. One could wonder why a loss-of-function polymorphism in TLR4 leads
to a lower incidence of acute rejection, but not graft failure. If there is a role for TLR4 polymor-
phisms in renal transplantation, it is probably a minor one that is overshadowed by other
immune and non-immune phenomena that take place in the graft. Finally, Krüger et al. [13],
in line with our study, did not find an association of TLR5 p.Arg392Ter with renal transplant
outcomes. Even though experimental renal transplantation studies have consistently shown
that TLR engagement can break allograft tolerance while inhibition of for instance TLR2 and
-4 signalling improves allograft acceptance [48,53,64–66], in human renal transplantation the
consequences of non-synonymous SNPs in TLR genes appear to be not as devastating for
transplant outcome.
In conclusion, TLR gene polymorphisms are enriched in patients with end-stage renal dis-
ease and may contribute to the final common pathway of renal injury whereas after renal trans-
plantation, this effect for the TLR gene polymorphisms was not observed. This difference in
effect size by the TLR gene polymorphisms highlights that the development of chronic kidney
disease of the native kidneys and chronic kidney disease in the context of renal transplantation
might be explained by different risk factors.
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Table 8. (Continued)
Gene HGVS name Author, year Reference Country Native / Transplant Disease Controls Effect of the minor allele
TLR5 p.Phe616Leu - - - - - - -
TLR6 p.Ser249Pro - - - - - - -
TLR7 p.Gln11Leu - - - - - - -
TLR8 p.Met1Val - - - - - - -
1SNP in donors
2SNP in recipients.
Native = renal diseases of the native kidneys, transplant = renal diseases after transplantation, GN = glomerulonephritis, Healthy = healthy controls,
PN = pyelonephritis, CKD = chronic kidney disease, DGF = delayed graft function, AR = acute rejection, GF = graft failure.
doi:10.1371/journal.pone.0139769.t008
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